Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $17.30 down -0.17% from its previous closing price of $17.33. In other words, the price has decreased by $-0.17 from its previous closing price. On the day, 0.82 million shares were traded. AVDL stock price reached its highest trading level at $17.65 during the session, while it also had its lowest trading level at $16.7.
Ratios:
For a deeper understanding of Avadel Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on March 05, 2024, Reiterated its Outperform rating but revised its target price to $29 from $27 previously.
On March 05, 2024, Needham reiterated its Buy rating and also lowered its target price recommendation from $20 to $22.
H.C. Wainwright reiterated its Buy rating for the stock on March 05, 2024, while the target price for the stock was revised from $21 to $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 16 ’24 when MCHUGH THOMAS S bought 2,000 shares for $14.50 per share. The transaction valued at 29,000 led to the insider holds 80,500 shares of the business.
McCamish Mark Anthony sold 75,000 shares of AVDL for $1,089,750 on Dec 28 ’23. The Director now owns 67,025 shares after completing the transaction at $14.53 per share. On Aug 14 ’23, another insider, MCHUGH THOMAS S, who serves as the Chief Financial Officer of the company, bought 2,000 shares for $14.45 each. As a result, the insider paid 28,900 and bolstered with 78,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1566982016 and an Enterprise Value of 1497307008. For the stock, the TTM Price-to-Sale (P/S) ratio is 58.79 while its Price-to-Book (P/B) ratio in mrq is 18.75. Its current Enterprise Value per Revenue stands at 53.546 whereas that against EBITDA is -11.003.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.61, which has changed by 0.69774294 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $18.85, while it has fallen to a 52-week low of $9.50. The 50-Day Moving Average of the stock is 11.15%, while the 200-Day Moving Average is calculated to be 27.46%.
Shares Statistics:
For the past three months, AVDL has traded an average of 1.24M shares per day and 1297500 over the past ten days. A total of 89.83M shares are outstanding, with a floating share count of 70.52M. Insiders hold about 25.78% of the company’s shares, while institutions hold 53.01% stake in the company. Shares short for AVDL as of 1711584000 were 10394704 with a Short Ratio of 8.37, compared to 1709164800 on 10741273. Therefore, it implies a Short% of Shares Outstanding of 10394704 and a Short% of Float of 11.57.
Earnings Estimates
Currently, 9 analysts are dedicated to thoroughly evaluating and rating the performance of Avadel Pharmaceuticals plc (AVDL) in the stock market.On average, analysts expect EPS of $-0.21 for the current quarter, with a high estimate of $-0.02 and a low estimate of $-0.31, while EPS last year was $-0.48. The consensus estimate for the next quarter is $-0.12, with high estimates of $-0.02 and low estimates of $-0.17.
Analysts are recommending an EPS of between $-0.05 and $-1.02 for the fiscal current year, implying an average EPS of $-0.4. EPS for the following year is $1.02, with 7 analysts recommending between $2.45 and $0.26.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $176.8M, while the lowest revenue estimate was $146.5M, resulting in an average revenue estimate of $162.18M. In the same quarter a year ago, actual revenue was $27.96M, up 480.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $291.9M in the next fiscal year. The high estimate is $334.2M and the low estimate is $240M. The average revenue growth estimate for next year is up 80.00% from the average revenue estimate for this year.
